Last $29.22 USD
Change Today +0.12 / 0.41%
Volume 109.7K
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Open
$29.04
Previous Close
$29.10
Day High
$29.47
Day Low
$28.85
52 Week High
11/22/13 - $37.24
52 Week Low
05/7/14 - $23.90
Market Cap
921.2M
Average Volume 10 Days
142.4K
EPS TTM
$-0.66
Shares Outstanding
31.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

684 Employees
Last Reported Date: 03/11/14
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $469.2K
Executive Vice President of Research & Develo...
Total Annual Compensation: $459.2K
Consultant
Total Annual Compensation: $353.8K
Compensation as of Fiscal Year 2013.

genomic health inc (GHDX) Key Developments

Genomic Health, Inc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2014

Genomic Health Inc. reported unaudited consolidated earnings results for the second quarter and six months June 30, 2014. For the quarter, the company reported total revenues of $70.477 million against $63.691 million a year ago. Loss from operations was $4.611 million against $2.911 million a year ago. Loss before income taxes was $4.530 million against $2.939 million a year ago. Net loss was $4.618 million against $2.994 million a year ago. Basic and diluted net loss per share was $0.15 against $0.10 a year ago. For six months, the company reported total revenues of $137.479 million against $126.785 million a year ago. Loss from operations was $11.805 million against $3.800 million a year ago. Loss before income taxes was $11.9 million against $3.769 million a year ago. Net loss was $12.063 million against $3.877 million a year ago. Basic and diluted net loss per share was $0.39 against $0.13 a year ago.

Genomic Health Inc. Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX(R) Prostate Cancer Test with Multiple Clinical Endpoints

Genomic Health Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(R) Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a predictor of biochemical recurrence, a rise in prostate-specific antigen (PSA) following surgery, which is a measure of longer-term outcomes for aggressive disease. It also reconfirmed the test's ability to predict adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco (UCSF). Additional, important endpoints of this landmark prostate cancer study include the development of metastatic disease and outcomes in African-American patients. Genomic Health and CPDR have submitted the results from this study for medical meeting presentation later this year. The CPDR is a multi-disciplinary prostate cancer research program of the Department of Surgery, USU, the Department of Defense's federal health sciences university, and it is a collaboration with The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., a private, not-for-profit organization authorized by Congress to support medical research and education at the Uniformed Services University of the Health Sciences.

Genomic Health Inc. to Report Q2, 2014 Results on Aug 07, 2014

Genomic Health Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $29.22 USD +0.12

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $23.05 USD +0.075
LipoScience Inc $2.90 USD -0.015
NanoString Technologies Inc $11.20 USD -0.24
NeoGenomics Inc $5.42 USD 0.00
Veracyte Inc $12.77 USD +0.34
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.